Xarelto, a blood thinner, has been subject to numerous class action lawsuits in recent years. Janssen Pharmaceuticals, a Belgian research and development division of Johnson & Johnson, has been accused of failing to inform consumers and doctors of potentially serious and life-threatening side effects such as uncontrolled and irreversible internal bleeding. Janssen has also been accused of failing to provide physicians with adequate solutions for this type of bleeding. These numerous class action lawsuits have been streamlined into multiple “districts” of litigation to better serve clients. The Zarelto story closely resembles that of another controversial blood thinner, Pradaxa (Dabigatran). Like the Xarelto case, Pradaxa caused similar side effects and once again the manufactures were accused of not warning doctors and patients about the potential risks of internal bleeding. Thousands of lawsuits were filed against the manufacturer; these claims increased once the risks were made widely known to the public. Due to the similarity of these two cases, experts suggested that the same magnitude of claims will be filed against the makers of Xarelto.